Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : HGR - Undervalued at 15 ( acquired novacare/will 2x reven -- Ignore unavailable to you. Want to Upgrade?

To: Sleepman who wrote (12)	1/7/2000 3:10:00 PM
From: Area51	Respond to of 14

I took an initial position here. I looked into it around 12 and was interested then. Just reading the latest press release, 0.63 in FY 99 with 25% growth would justify a price of 12(Book value about $9). I wouldn't mind picking up some more around 3 if the irrational selling continues. Good Luck, Area51

To: Sleepman who wrote (12)	1/7/2000 6:41:00 PM
From: Ed Ajootian	Respond to of 14

Dan, They are having growing pains. Nothing wrong with that, but the analysts despise companies that do not whisper warnings of such things in their ears prior to them finishing the quarter. If the company gives absolutely no guidance to the analysts about problems it is having, the net result is what you saw today, and everyone --- the company, the analysts, and the shareholders --- all look like a horse's ass. This problem is particularly harsh for HGR due to the high percentage of their shares that are held by institutions. Institututions are less patient with bad news because the fund managers want to make their bonuses _this year and don't care how much it may go up in 2 -- 3 years. Have a great weekend!